Center of Innovation in Long-Term Services and Supports, U.S. Department of Veterans Affairs Medical Center, Providence, Rhode Island.
Center for Gerontology and Healthcare Research, Brown University School of Public Health, Providence, Rhode Island.
J Gerontol A Biol Sci Med Sci. 2019 Jan 16;74(2):219-225. doi: 10.1093/gerona/gly044.
To develop a score to predict mortality using the Minimum Data Set 3.0 (MDS 3.0) that can be readily calculated from items collected during nursing home (NH) residents' admission assessments.
We developed a training cohort of Medicare beneficiaries newly admitted to United States NHs during 2012 (N = 1,426,815) and a testing cohort from 2013 (N = 1,160,964).
Data came from the MDS 3.0 assessments linked to the Medicare Beneficiary Summary File. Using the training dataset, we developed a composite MDS 3.0 Mortality Risk Score (MRS3) consisting of 17 clinical items and patients' age groups based on their relation to 30-day mortality. We assessed the calibration and discrimination of the MRS3 in predicting 30- and 60-day mortality and compared its performance to the Charlson Comorbidity Index and the clinician's assessment of 6-month prognosis measured at admission.
The 30- and 60-day mortality rates for the testing population were 2.8% and 5.6%, respectively. Results from logistic regression models suggest that the MRS3 performed well in predicting death within 30 and 60 days (C-Statistics of 0.744 [95% confidence limit (CL) = 0.741, 0.747] and 0.709 [95% CL = 0.706, 0.711], respectively). The MRS3 was a superior predictor of mortality compared to the Charlson Comorbidity Index (C-statistics of 0.611 [95% CL = 0.607, 0.615] and 0.608 [95% CL = 0.605, 0.610]) and the clinicians' assessments of patients' 6-month prognoses (C-statistics of 0.543 [95% CL = 0.542, 0.545] and 0.528 [95% CL = 0.527, 0.529]).
The MRS3 is a good predictor of mortality and can be useful in guiding decision-making, informing plans of care, and adjusting for patients' risk of mortality.
开发一个基于最小数据集 3.0(MDS 3.0)的评分系统,用于预测死亡率,该评分系统可通过在疗养院(NH)居民入院评估期间收集的项目进行计算。
我们开发了一个培训队列,其中包括 2012 年新进入美国 NH 的医疗保险受益人(N=1,426,815),以及一个来自 2013 年的测试队列(N=1,160,964)。
数据来自 MDS 3.0 评估,与医疗保险受益人的摘要文件相关联。使用训练数据集,我们开发了一个由 17 个临床项目和患者年龄组组成的复合 MDS 3.0 死亡率风险评分(MRS3),这些项目和年龄组与 30 天死亡率有关。我们评估了 MRS3 在预测 30 天和 60 天死亡率方面的校准和区分能力,并将其与 Charlson 合并症指数和入院时临床医生对 6 个月预后的评估进行了比较。
测试人群的 30 天和 60 天死亡率分别为 2.8%和 5.6%。逻辑回归模型的结果表明,MRS3 在预测 30 天和 60 天内死亡方面表现良好(C 统计量分别为 0.744 [95%置信区间(CL)=0.741, 0.747] 和 0.709 [95% CL = 0.706, 0.711])。与 Charlson 合并症指数(C 统计量分别为 0.611 [95% CL = 0.607, 0.615] 和 0.608 [95% CL = 0.605, 0.610])和临床医生对患者 6 个月预后的评估相比,MRS3 是死亡率的更好预测指标(C 统计量分别为 0.543 [95% CL = 0.542, 0.545] 和 0.528 [95% CL = 0.527, 0.529])。
MRS3 是死亡率的良好预测指标,可用于指导决策、制定护理计划,并调整患者的死亡率风险。